These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 27910121)

  • 1. Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals.
    Kozbial K; Aberle SW; Susser S; Al-Zoairy R; Moser S; Stättermayer AF; Maieron A; Gschwantler M; Stauber R; Graziadei I; Zoller H; Beinhardt S; Holzmann H; Munda-Steindl P; Hofer H; Sarrazin C; Ferenci P
    Aliment Pharmacol Ther; 2017 Jan; 45(2):373-375. PubMed ID: 27910121
    [No Abstract]   [Full Text] [Related]  

  • 2. Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral.
    Rutter K; Hofer H; Beinhardt S; Dulic M; Gschwantler M; Maieron A; Laferl H; Stättermayer AF; Scherzer TM; Strassl R; Holzmann H; Steindl-Munda P; Ferenci P
    Aliment Pharmacol Ther; 2013 Jul; 38(2):118-23. PubMed ID: 23710895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha-2b and ribavirin for retreatment of chronic hepatitis C.
    Dettmer RM; Reinus JF; Clain DJ; Aytaman A; Levendoglu H; Bloom AA; Isaacson MP; Spinnell M; Meyer D; Sarabanchong V; Zhang Y; Garcia-Carrasquillo RJ; Markowitz DD; Magun AM; Worman HJ
    Hepatogastroenterology; 2002; 49(45):758-63. PubMed ID: 12063985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment of chronic hepatitis C virus infection.
    Lim JK; Imperial JC; Keeffe EB
    Rev Gastroenterol Disord; 2004; 4(3):97-103. PubMed ID: 15359210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.
    Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V
    Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
    Fabrizi F; Messa P
    Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
    Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.
    Trapero-Marugán M; Mendoza J; Moreno Monteagudo JA; Chaparro M; García-Buey L; González-Moreno L; Borque MJ; Moreno-Otero R
    J Clin Pharm Ther; 2011 Dec; 36(6):695-703. PubMed ID: 21175705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
    Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
    World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.
    Seo KI; Yun BC; Li WJ; Lee SU; Han BH; Park ET
    Clin Mol Hepatol; 2017 Mar; 23(1):74-79. PubMed ID: 28259115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon retreatment on interferon-resistant patients with chronic hepatitis C.
    Egusa K; Kondo J
    Acta Med Okayama; 2003 Jun; 57(3):151-8. PubMed ID: 12908013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with peginterferon and ribavirin in chronic hepatitis C.
    Jo YM; Lee SW; Han SY; Baek YH; Kim SY; Kim WJ; Ahn JH; Lee JY
    World J Gastroenterol; 2015 Feb; 21(6):1994-9. PubMed ID: 25684969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
    Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
    Abbas Z; Hamid SS; Tabassum S; Jafri W
    J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
    Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC
    N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.